提醒:代购产品,无质量问题不接受退换货,下单前请仔细核对信息。下单后请及时联系客服 核对商品价格,订单生效后再付款。
Glen research/dC-CPG 2000/1kit/20-2012-02
价格:

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号:
品牌:
会员服务:
尊享会员价
贵宾专线
运费优惠
闪电退款
福利优惠
上门换新
友情提示
以上价格仅为参考,请联系客服询价。
免费咨询热线
4000-520-616
产品说明
Technical DocumentsDescriptionDetailsRelated ProductsProduct FAQsTechnical DocumentsSafety Data SheetDescriptionAll Glen Research CPG supports use the standard long chain alkylamino (lcaa) linker but differ in the glass pore size, 500Å, 1000Å or 2000Å. The 500Å support is appropriate for shorter sequences, while the 1000Å supports perform better in the synthesis of longer (>30-mer) DNA sequences. The 2000Å support is best for very long (>150-mer) oligonucleotides. We have instituted an additional QC test for supports to show the length of oligo that can be prepared before a drop-off in coupling due to steric effects begins to occur. The drop-off point is recorded in the Certificate of Analysis. All Glen Research supports are fully end-capped to ensure that the CPG surface is totally inert, thereby avoiding the introduction of impurity sequences containing deletions at the 3"-terminus.DetailsUsageCoupling: No changes needed from standard method recommended by synthesizer manufacturer.Deprotection: Deprotect using the protocol required by the nucleobases.SpecificationsStorageControlled room temperature or lower, dryRelated Products/*.carousel-inner .active.left{ left: -33%; }*//*.carousel-inner .active.right { left: 33%;}*//*.carousel-inner .next { left: 33% }*//*.carousel-inner .prev { left: -33%}*//*.carousel-control.left{ background-image: none; position: relative; float: left; }*//*.carousel-control.right { background-image: none; position: relative; float: right;}*//*.carousel-inner .item { background: white;}*//*.block.upsell {display: none; }*//*.products .product-item-details {*//*padding-left: 10px;*//*padding-right: 10px;*//*background: #efeeee;*//*color: #58595b;*//*font-size: 18px;*//*padding: 20px 10px;*//*border-radius: 0 0 3px 3px; }*//*.owl-wrapper-outer{*//*overflow: hidden;*//*position: relative;*//*width: 100%;*//*}*//*.block.related .owl-carousel .owl-item {*//*padding: 0px 7px;*//*}*/Related Products dC-CE PhosphoramiditeCatalog #: 10-1010dA-CPG 500Catalog #: 20-2000dA-CPG 1000Catalog #: 20-2001dA-CPG 2000Catalog #: 20-2002dC-CPG 500Catalog #: 20-2010dC-CPG 1000Catalog #: 20-2011Ac-dC-CPG 500Catalog #: 20-2013Ac-dC-CPG 1000Catalog #: 20-2015Product FAQsHow do the 1000Å and 2000Å supports compare in the synthesis of long oligos?Do you recommend any changes to the cycle for long oligos?In one comparison several years ago, a customer compared 1000Å, 2000Å and a low-loaded 500Å CPG for the synthesis of 200 and 400mers. Only in the case of the 2000&Aring CPG could the 200mer product be seen on a gel although the other supports did make product since it could be amplified by PCR. The 400mers could not be seen but could be amplified by PCR.For the synthesis of long oligos, we recommend increasing the coupling wait step from 15 seconds to at least 30 seconds. I believe this is important later in the synthesis. Also, we recommend the use of DMAP in the Cap B solution or, if methylimidazole has to be used, increasing the capping wait step to 45 seconds. With incomplete capping, you are going to be making oligos contaminated with deletion mutations. I know DMAP has been accused of causing base modification of dG sites leading to fluorescent bands on gels but it is still the most effective capping activator. I also would recommend, if possible, an extended capping of the support (20 minutes) before the DMT is removed in the first cycle. The 1000Å and especially the 2000Å supports are very fragile and can be damaged in transit. This capping step deactivates any fresh surfaces caused by fractures. TWIST columns are assembled with 20µm frits to retain any fines coming from these friable supports.||REFERENCE(S):J.S. Eadie and D.S. Davidson, Nucleic Acids Res., 1987, 15, 8333..catalog-product-faqs{width: 100%;}.faq_list .faqItem .faqTitle::before {content: "e250";font-family: "Glyphicons Halflings";font-size: 14px;right: 18px;position: absolute;top: 30%;-moz-transform: rotate(0);-webkit-transform: rotate(0);transform: rotate(0);-moz-transition: all ease-in-out 0.2s;-webkit-transition: all ease-in-out 0.2s;transition: all ease-in-out 0.2s;}#catalog_custom_product_faqs{width: 100%;}

Glen research对我们的员工,我们的客户和环境的承诺


Maravai LifeSciences致力于在所有业务活动中成为环境,健康与安全(EHS)管理方面的领导者,
符合Maravai LifeSciences的商业利益和行为准则。

我们承诺:

雇员

我们将通过提供零伤害的工作场所来预防伤害和疾病
并促进健康的生活方式,从而对每位员工产生积极影响我们将确保我们的员工具有
执行此政策的意识,工具和知识

可持续发展

我们将通过使用确保安全,效率和社会责任的商业惯例,以
现在和将来保护我们的员工,社区,股东和环境的方式,进行可持续思考和采取行动

合规

我们将遵守适用的法律和法规,同时提供程序和程序以确保我们的遵守。

文化

我们将通过停工授权,
查明根本原因并采取纠正措施,倡导一种不容忍不安全状况和行为的文化

业务整合

我们会将环境,健康和安全考虑因素纳入我们的业务活动。

顾客

我们将与客户紧密合作,以帮助他们满足其环境,健康和安全需求。

供应商和承包商

我们将与我们的供应商和承包商合作,以改善环境,健康和安全绩效。

社区与政府

我们将参与社区和政府的环境,健康和安全计划。


这些价值观得到了Maravai高层管理人员的重视,并在组织内的所有责任级别得到强调。

卡尔·赫尔(Carl Hull)
首席执行官


客服在线
service-logo
已有 人查看该问题
tel
全国免费服务热线
4000-520-616
微信公众号
关注我们
手机扫码,关注动态